As of November 10, 2026, Braveheart Bio, Inc. is a publicly traded company (Nasdaq: BRVE). The largest holder reporting an active stake on Schedule 13D is OrbiMed, at 13.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Jiangsu Hengrui Pharmaceuticals Co., Ltd. (8.2%), Fidelity (FMR) (8.2%), Frazier Life Sciences Public Fund, L.P. (5.5%) (Schedule 13D/A, September 10, 2026).
Is this your company?
About to sign with, pay or invest in Braveheart Bio, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Braveheart Bio, Inc. a real, registered company?
- Braveheart Bio, Inc. files with the SEC under CIK 2131524 (its SEC filings).
- Its shares are listed under the ticker BRVE on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Braveheart Bio, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Jiangsu Hengrui Pharmaceuticals Co., Ltd. (filed 2026-11-09).
Who are Braveheart Bio, Inc.'s owners and officers?
Braveheart Bio, Inc.: incorporated in Delaware; business address in San Francisco, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-11-09).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-09 | Jiangsu Hengrui Pharmaceuticals Co., LTD. | 8.2% |
| Schedule 13G, 2026-11-05 | Fmr LLC | 8.2% |
| Schedule 13D/A, 2026-09-10 | Orbimed Advisors LLC | 13.5% |
| Schedule 13D, 2026-08-18 | Orbimed Advisors LLC | 17.2% |
| Schedule 13G, 2026-08-14 | Frazier Life Sciences Public Fund, L.P. | 5.5% |
| Schedule 13D, 2026-08-14 | Ah Bio Fund Iv, L.P. | 11.4% |
Questions about who owns Braveheart Bio, Inc.
Who owns Braveheart Bio, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Braveheart Bio, Inc.: Orbimed Advisors LLC (13.5%, Schedule 13D/A, filed 2026-09-10), Ah Bio Fund Iv, L.P. (11.4%, Schedule 13D, filed 2026-08-14), Jiangsu Hengrui Pharmaceuticals Co., LTD. (8.2%, Schedule 13G, filed 2026-11-09), Fmr LLC (8.2%, Schedule 13G, filed 2026-11-05) and Frazier Life Sciences Public Fund, L.P. (5.5%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Braveheart Bio, Inc.?
By the share each holder's latest filing reports, the largest holders of Braveheart Bio, Inc. on this page are Orbimed Advisors LLC (13.5%), Ah Bio Fund Iv, L.P. (11.4%) and Jiangsu Hengrui Pharmaceuticals Co., LTD. (8.2%).
When did Orbimed Advisors LLC buy into Braveheart Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D, filed 2026-08-18, reporting 17.2%; its latest, Schedule 13D/A filed 2026-09-10, reports 13.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Braveheart Bio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Braveheart Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Braveheart Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Braveheart Bio, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Forbion Ventures Fund VII Cooperatief U.A., a 10% owner: 40,052,048 shares (44.5% of shares outstanding), 21,361,092 held directly and 18,690,956 indirectly, on a joint filing (Form 4, 2026-08-07).
- Forbion Ventures VII Management B.V., a 10% owner: 40,052,048 shares (44.5% of shares outstanding), 21,361,092 held directly and 18,690,956 indirectly, on a joint filing (Form 4, 2026-08-07).
- Forbion Growth Opportunities Fund III Cooperatief U.A., a 10% owner: 40,052,048 shares (44.5% of shares outstanding), 21,361,092 held directly and 18,690,956 indirectly, on a joint filing (Form 4, 2026-08-07).
- Forbion Growth III Management B.V., a 10% owner: 40,052,048 shares (44.5% of shares outstanding), 21,361,092 held directly and 18,690,956 indirectly, on a joint filing (Form 4, 2026-08-07).
- AH Equity Partners Bio IV, L.L.C., a 10% owner: 10,232,420 shares (11.4% of shares outstanding), held indirectly through By AH Bio Fund IV, L.P., on a joint filing (Form 4, 2026-08-11).
Shares outstanding: 90,038,969 as of 2026-09-03, from the company's latest SEC cover page.
How much has Braveheart Bio, Inc. raised?
Latest IPO step: Braveheart Bio, Inc. filed its final IPO prospectus, ticker BRVE (424B4, 2026-08-06).
IPO filings: 424B4, 2026-08-06, S-1/A, 2026-07-30, S-1, 2026-07-15; ticker BRVE on Nasdaq Global Market.
Keep reading
More on Braveheart Bio, Inc. and the records around it.
Braveheart Bio, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- IPO filing Aug 2026
Companies that share a holder
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. also filed stake reports on 1 other company: Kailera Therapeutics, Inc. (Aug 2026)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/braveheart-bio